Lung Cancer News

HONOLULU — Adults faced a higher risk for incident cancer if their Morningness-Eveningness Questionnaire score deviated from the median score, signaling circadian disturbances, according to research presented at the CHEST Annual Meeting.

MADRID — The combination of amivantamab and lazertinib improved PFS compared with osimertinib as first-line treatment for EGFR-mutated advanced non-small cell lung cancer, according to study results presented at ESMO Congress.

MADRID — The addition of amivantamab to first-line chemotherapy improved outcomes for patients with advanced non-small cell lung cancer and EGFR exon 20 insertions, according to randomized phase 3 study results presented at ESMO Congress.

MADRID — The addition of nivolumab to neoadjuvant chemotherapy, followed by adjuvant nivolumab, improved outcomes for patients with untreated resectable non-small cell lung cancer, randomized phase 3 study results showed.

MADRID — Tarlatamab exhibited antitumor activity among patients with small cell lung cancer who received prior treatment, according to results of the DeLLphi-301 study presented at ESMO Congress.

The FDA approved pembrolizumab plus platinum-containing chemotherapy as neoadjuvant therapy, followed by single-agent pembrolizumab as adjuvant therapy after surgery for adults with resectable non-small cell lung cancer.

Lung cancer incidence remained higher among U.S. women aged younger than 50 years compared with men, according to a research letter published in JAMA Oncology.

The FDA approved encorafenib plus binimetinib for treatment of certain patients with non-small cell lung cancer.

Pembrolizumab as neoadjuvant and adjuvant therapy significantly extended OS among adults with resectable stage II, IIIA or IIIB non-small cell lung cancer, according to the agent’s manufacturer.

HONOLULU — A model that incorporates demographic and smoking history data has identified regions populated with individuals eligible for lung cancer screening, according to study results presented at the CHEST Annual Meeting.